<DOC>
	<DOCNO>NCT02406989</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multiple-ascending dose study MS-553 healthy volunteer . Endpoints safety , tolerability , pharmacokinetics . Subjects dose 14 day .</brief_summary>
	<brief_title>A Multiple-Ascending Dose Study MS-553 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>In good general health BMI 18 32 kg/m2 . Females must nonpregnant , nonlactating , postmenopausal least 2 year surgically sterilize least 6 month prior History skin rash , migraine , clinically significant ocular disease , condition predispose QT prolongation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>